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Abstract Introduction: In order to improve the outcomes of urological cancers,
guidelines published by the National Institute of Clinical Excellence encourage the
management of cancer patients by specific Multi-Disciplinary Teams (MDTs) with
discussion of cancer patients at MDT Meetings. The aim of this prospective study
was to examine the changes in management resulting from review at MDT Meetings
in our unit.
Methods: Over a six month period 124 cancer cases were discussed at 10 meetings.
Prior to the meetings consultants completed a form stating their proposed
management and whether they thought this would be changed after discussion.
At the meeting histological, radiological and clinical data were reviewed and
a collective decision about the optimal treatment was made. Any changes were
recorded.
Results: Two of 124 cases had their clinical management changed as a result of the
meeting. These were identified (amongst 10 others) as potential ‘change cases’
prior to the meeting. Four changes were made to histological reports and 1 to
radiology; none of these affected clinical management.
Conclusion: Discussion of cancer cases at MDMs made no difference to the clinical
management in over 98% of cases. Consultants correctly identified cases requiring
discussion, indicating that a selective rather than blanket approach would be
appropriate. This has the potential to reduce the considerable costs involved
without affecting patient care.
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UK Guidelines by the National Institute for Clinical
Excellence (NICE) published in the document
Improving outcomes in urological cancers promote
the formation of local Multidisciplinary Teams
(MDTs) made up of designated specialists to col-
lectively manage all cases of urological cancer
(both new and existing).1 It is noted that although
urological malignancies account for 11.7% of can-
cer deaths2 urological services have lagged behind
other specialities in forming co-ordinated MDTs.1
The guidelines encourage regular MDT meetings
where relevant information is gathered and cases
are discussed with a view to making collective
evidence-based decisions.1 However, there is a lack
of evidence supporting the idea that MDT meetings
will improve cancer outcomes in urology.1
The aim of this prospective study was to
examine the impact of MDT meetings in a District
General Hospital with respect to changes in man-
agement resulting from case review.
Methods
MDT meetings in our unit occupy one session each
fortnight and are attended by three consultants in
urology, a lead clinician, a pathologist, a radiolo-
gist, an oncologist, two urology nurse practitioners
and junior staff. Meetings were analysed prospec-
tively over a period of 6 months. Prior to each
meeting, individual consultants were requested to
complete a pro forma for each case under their
care to be discussed stating the patient’s detailsand diagnosis, the consultant’s own management
plan and whether he thought this had potential to
be changed. At each meeting one of the authors
recorded any changesmade to pathology or radiological
reports following MDT review and compared the agreed
management plan for each case to that proposed by
the clinician.
Results
During the study 124 urological cancer cases were
discussed; consultants identified 12 of these as
potential ‘‘case changes’’ prior to the meetings.
There were two clinical management changes as
a result of MDT discussion, both of which were
from the ‘‘case change’’ group (see Table 1).
There were four histological and one radiolog-
ical report changes (see Table 1); none of these
had any alteration on clinical management.
Conclusion
It appears that the vast majority of newly di-
agnosed urological cancer cases do not require
discussion at an MDT meeting, and those that do
benefit can be filtered out by consultants in
advance. Whilst it may be the case that a longer
study would have revealed more pertinent man-
agement changes, possibly from larger numbers of
diagnostic reviews, we feel that this is unlikely and
the discussion of every single case not justified.Table 1 Changes arising from the meetings
Change Notes
Histological
1. Grade 2 to Grade 3 bladder cancera 86-year-old male e inoperable tumour
2. Grade 1 to Grade 2 bladder cancera 77-year-old male (T1 tumour) e undergoing surveillance
and intravesical chemotherapy
3. Gleason 3C 5 to 4C 5 prostate cancera 85-year-old male e undergoing hormone manipulation
4. Gleason 2C 2 to 3C 2 prostate cancera 66-year-old male e suitable for radical prostatectomy
Radiological
1. Renal cysta,b Reported as benign but queried by Urologist. Later
considered benign therefore no management change
Management
1. Radiotherapy cf symptomatic treatmentb 84-year-old male with locally advanced bladder cancer;
Outcome e death from cardiac causes 2 months later
2. Regular review cf surgeryb 24-year-old male with a suspicious testicular lesion on USS;
Outcome e continues to be under review 12 months later
a Made no difference to management.
b Identified by consultants as possible ‘‘case changes’’ prior to the meetings.
The impact of ‘‘multidisciplinary team meetings’’ 123Multidisciplinary team management (with regu-
lar meetings) is a fundamental pillar of Improving
outcomes in urological cancers and is becoming
more widespread across a variety of specialities1
indeed the concept has been described as a fourth
cancer treatment modality after surgery, chemo-
therapy and radiotherapy.3 The knowledge that
a panel of specialists discuss every cancer case is
reassuring both to patients and clinicians alike4 and
will be amongst patient expectations increasingly
so in the future.5 This can be seen as part of the
movement towards a consultant-delivered service.
By working together, all modalities can be
considered from the outset allowing improved
planning and preventing any compromise later on
in a patient’s treatment.4 The administrative
aspect has potential to facilitate auditing and
monitoring of local services, brings together all
aspects of patient care and prevents loss of follow-
up, forming a ‘‘co-ordination’’ mechanism6 which
improves feedback and ultimately, clinical out-
comes.7 There is also a highly educational value to
be attached for all attendees.8
There are, however, hurdles to overcome partic-
ularly in terms of funding and manpower,4,9,10 the
latter necessitating co-ordinationwith other cancer
groups. To date, few centres have been allocated
extra resources for meetings; ours has been fortu-
nate to receive a dedicated session every 2 weeks.
Specialist uropathologists and uroradiologists re-
viewing all relevant cases prior to meetings could
reduce meeting times without compromising pa-
tient care. Attendance at these sessions inevitably
takes time away from the provision of other services
such as clinics or operating lists.
The introduction of MDT meetings is an expen-
sive exercise: NICE have calculated this to be £6.4
million on a national scale to cover co-ordinators,
additional staff time and additional consultantsessions.1 The results of this study suggest that
the costs are not well defensible.
Our study shows that consultants are quite
capable of identifying cases that require discussion
with other team members. The small number of
management changes as a result of MDT meeting
(less than 2% of cases discussed) had been recog-
nised in this manner; adopting a targeted approach
could make savings on resources without adversely
affecting patient care provided all cancer man-
agement decisions are continued to be brought to
the attention of a consultant. The low rate of
changes may well be cited as a measure of the
success of MDT meetings: an advantage that would
not be lost.
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